Coronavirus

Todos Medical Announces First Two Contracts for PCR-based MonkeyPox Testing at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics

New York, NY, and Tel Aviv, ISRAEL, Aug. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive…

4 years ago

AnPac Bio Announces Appointment of New Directors and Co-Chief Executive Officer

PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a…

4 years ago

Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics

RTHM collaborating on Tollovid™ 3CL inhibitor immune support supplement case studiesTollovid biomarker data to support potential structure-function claims in Long…

4 years ago

Novel Carbohydrate Antiviral Drug Candidate Acts Through Galectin Inhibition to Block SARS-CoV-2 Coronavirus

ProLectin-M, a new class of oral antiviral drug BOSTON, MASSACHUSETTS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (Symbol: BIXT)…

4 years ago

Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET

Key Proposal #2 Needs an Additional 0.9% of Outstanding Shares Votes to Pass Leading Independent Proxy Advisory Firms, ISS and…

4 years ago

Alimera Sciences Announces Second Quarter 2022 Financial Results

Consolidated Net Product Revenue of $14.6 Million up 36% vs. Second Quarter of 2021U.S. End User Demand up 45% vs.…

4 years ago

Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022

Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness  Study Data Indicate Symphony IL-6 Test Could be…

4 years ago

Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024

NORCROSS, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins,…

4 years ago

Aligos Therapeutics Initiates 12-Week Dosing Cohort in Phase 1b Study Evaluating Its Class II Capsid Assembly Modulator, ALG-000184

SOUTH SAN FRANCISCO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company…

4 years ago